down arrow

Leap Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US52187K2006
USD
1.27
0.1 (8.55%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.211.42

52 Week

0.223.69
Valuation
Technical
Day's Volume

CASH

6.29 M

Shareholding (Mar 2025)

FII

5.32%

Held by 17 FIIs

DII

67.01%

Held by 10 DIIs

Promoter

20.26%

How big is Leap Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Leap Therapeutics, Inc. has a market capitalization of 15.61 million, with net sales of 0.00 million and a net profit of -69.18 million over the last four quarters. The company reported shareholder's funds of 35.05 million and total assets of 49.12 million as of Dec 24.

Market Cap: As of Jun 18, Leap Therapeutics, Inc. has a market capitalization of 15.61 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Leap Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -69.18 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 35.05 million and total assets of 49.12 million.

Read More

What does Leap Therapeutics, Inc. do?

22-Jun-2025

Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing cancer therapies that inhibit tumor-promoting pathways and activate the immune system. It operates as a micro-cap company with a market cap of $15.61 million and reported a net profit loss of $15 million as of March 2025.

Overview: Leap Therapeutics, Inc. is a biopharmaceutical company developing therapies to treat cancer by inhibiting tumor-promoting pathways and activating the immune system, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025). Market cap: USD 15.61 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making), Industry P/E: NA, Dividend Yield: 0.00%, Debt Equity: -1.54, Return on Equity: -331.91%, Price to Book: 0.75.<BR><BR>Contact Details: Address: 47 Thorndike St Ste B1-1, CAMBRIDGE MA: 02141-1799. Tel: 1 617 2524343. Website: https://www.leaptx.com/.

Read More

Who are in the management team of Leap Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Leap Therapeutics, Inc. includes Dr. Christopher Mirabelli (Chairman), Mr. Douglas Onsi (CEO), and several independent directors: Dr. Thomas Dietz, Dr. Monica Bertagnolli, Dr. James Cavanaugh, Dr. William Li, and Dr. Joseph Loscalzo. This team oversees the company's governance and strategic direction.

As of March 2022, the management team of Leap Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Christopher Mirabelli, Chairman of the Board<BR>- Mr. Douglas Onsi, President, Chief Executive Officer, and Director<BR>- Dr. Thomas Dietz, Lead Independent Director<BR>- Dr. Monica Bertagnolli, Independent Director<BR>- Dr. James Cavanaugh, Independent Director<BR>- Dr. William Li, Independent Director<BR>- Dr. Joseph Loscalzo, Independent Director<BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Leap Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

Leap Therapeutics, Inc. is currently considered overvalued due to unfavorable financial metrics and peer comparisons, with a year-to-date return of -89.25% compared to the S&P 500's 2.44%.

As of 12 August 2022, Leap Therapeutics, Inc. moved from a grade of risky to does not qualify. The company is currently considered overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.78, an EV to EBIT of 0.22, and an astonishing ROCE of 626.53%, although the ROE is notably negative at -331.91%.<BR><BR>In comparison to its peers, Leap Therapeutics, Inc. has a less favorable valuation with a peer EV to EBITDA of 0.2332, while companies like Precision BioSciences, Inc. show a more negative EV to EBITDA of -0.1189. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -89.25% compared to the index's 2.44%. Overall, the current valuation suggests that Leap Therapeutics, Inc. is overvalued in the market.

Read More

Is Leap Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of July 28, 2025, Leap Therapeutics, Inc. shows a mildly bearish trend, with significant year-to-date declines of -88.82% compared to a 12.22% gain in the S&P 500, influenced by daily moving averages and Bollinger Bands.

As of 28 July 2025, the technical trend for Leap Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal on the monthly. Moving averages indicate a mildly bearish stance on the daily timeframe. Bollinger Bands and OBV are also mildly bearish on the weekly, with no trend on the monthly for OBV. <BR><BR>In terms of performance, the stock has seen a significant decline year-to-date of -88.82%, compared to a positive return of 12.22% for the S&P 500. Over the past year, the stock is down -88.84%, while the S&P 500 has gained 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the Bollinger Bands.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 12 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-3.12

stock-summary
Return on Equity

-1,069.76%

stock-summary
Price to Book

2.07

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-17 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
338.08%
0%
338.08%
6 Months
242.78%
0%
242.78%
1 Year
-54.48%
0%
-54.48%
2 Years
-45.73%
0%
-45.73%
3 Years
121.52%
0%
121.52%
4 Years
-94.69%
0%
-94.69%
5 Years
-92.11%
0%
-92.11%

Leap Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Leap Therapeutics, Inc. technically bullish or bearish?

As of 28 July 2025, the technical trend for Leap Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal on the monthly. Moving averages indicate a mildly bearish stance on the daily timeframe. Bollinger Bands and OBV are also mildly bearish on the weekly, with no trend on the monthly for OBV. In terms of performance, the stock has seen a significant decline year-to-date of -88.82%, compared to a positive return of 12.22% for the S&P 500. Over the past year, the stock is down -88.84%, while the S&P 500 has gained 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the Bollinger Bands....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-24.21%
EBIT Growth (5y)
-158.78%
EBIT to Interest (avg)
-56.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.54
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
68.96%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.78
EV to EBIT
0.22
EV to EBITDA
0.22
EV to Capital Employed
1.40
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
626.53%
ROE (Latest)
-331.91%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 9 Schemes (7.41%)

Foreign Institutions

Held by 17 Foreign Institutions (5.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 17.41% vs -50.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.40",
          "val2": "-21.30",
          "chgp": "41.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.60",
          "val2": "-20.10",
          "chgp": "17.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.95% vs -49.08% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.10",
          "val2": "-86.60",
          "chgp": "19.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-67.60",
          "val2": "-81.40",
          "chgp": "16.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.40
-21.30
41.78%
Interest
0.00
0.00
Exceptional Items
-4.50
0.00
Consolidate Net Profit
-16.60
-20.10
17.41%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 17.41% vs -50.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-70.10
-86.60
19.05%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-67.60
-81.40
16.95%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.95% vs -49.08% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Leap Therapeutics, Inc. stock-summary
stock-summary
Leap Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Leap Therapeutics, Inc. is a biopharmaceutical company developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body’s immune system to identify and attack cancer. DKN-01 and TRX518 are its clinical stage programs. DKN-01 is a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). GITR is a receptor found on the surface of a wide range of immune cells.
Company Coordinates stock-summary
Company Details
47 Thorndike St Ste B1-1 , CAMBRIDGE MA : 02141-1799
stock-summary
Tel: 1 617 2524343
stock-summary
https://www.leaptx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."